Why AeroVironment Stock Crashed 27% in March

AeroVironment reported fiscal Q3 revenue of $408M (up 143% y/y; organic +38%) but posted a $179M loss (versus a $3M loss prior) and adjusted EPS of $0.64, missing consensus revenue of $476M and EPS $0.68. The company recorded a $151.3M goodwill impairment and $43.9M of other non-cash charges after the U.S. Space Force terminated a $1.7B BADGER contract; management cut FY revenue guidance to $1.85B–$1.95B from $1.95B–$2.0B, while bookings were $2.1B (book-to-bill 1.6) with a funded backlog of $1.1B.

Analysis

This outcome crystallizes a classic small-prime defense risk: technology development costs are being re-priced from captive government margin assumptions to a hybrid commercial-go-to-market that requires new sales channels, working capital, and customer-qualification timelines. Expect near-term margin pressure and slower cash conversion as product-specific tooling, certification and channel buildout shift cost from R&D capitalized assumptions into prolonged SG&A and inventory cycles.

Second-order winners will be large, diversified primes and avionics suppliers that can absorb phased-array and high-energy laser volume with minimal idiosyncratic program risk; they also have the balance-sheet optionality to buy program assets or partnerships to accelerate commercialization. Conversely, specialist subcontractors and COTS component vendors tied to single-program demand will see demand volatility, creating opportunities to renegotiate pricing or re-award work to larger suppliers.

Key catalysts to watch on a 3–12 month horizon are recompete timelines, any commercial anchor customers (telco, maritime, enterprise), and near-term booking composition — a shift in new awards from funded government work to commercial backlog would signal a longer, lower-margin growth path. Tail risks include further impairment cycles if commercialization fails and banks or primes tighten supplier financing; the most direct reversal would be a recompete win or a strategic OEM/distributor partnership that de-risks commercial sales channels and restores margin visibility.

Key Decisions for Investors

• Tactical short AVAV equity (or buy puts) sized 3–5% notional: target 30–45% downside over 6–12 months if backlogs re-price and guidance remains muted. Use a stop-loss at +20% vs entry or hedge with a short-dated call. Rationale: asymmetry from program de-risking failure and multiple compression on small-prime risk.
• Relative-value pair: short AVAV / long LHX (L3Harris) 1:1 dollar exposure for 6–12 months. Expect 15–25% outperformance from LHX capturing recompete share and lower customer-concentration premium; cap downside by scaling position if AVAV announces a commercial anchor.
• Cost-limited option spread: buy AVAV 6-month put / sell 3-month put (calendar put spread) to express downside while financing premium. Target payoff >2x if shares retest recent lows; breakeven defined by net debit — keep position size <3% book.
• Event-driven long (conditional): accumulate on clear commercial distribution partnership or recompete award — tranche into position with 40% profit target and 25% stop. This converts speculative program optionality into a liquidity/cash-flow story with defined upside.